TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of successful tibia unions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: haemodynamical changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety and tolerability of the decitabine regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Qaw
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Maximum Serum Leuprolide Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Half-life (t½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinical activity of vitiligo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevation of serum Vitiligo activity markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevation of PCR levels of serum Vitiligo activity markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: myocardial mitochondrial dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: At least Very good partial remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: IVF results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hs-troponin 1 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline tumor hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants with anti-HBs ≥10mUI/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With no Heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Patients With Major Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline in Forced expiratory volume in 1 second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of Participants With Confirmed Cardiovascular (CV) Death Through Day 180
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Worsening of Heart Failure (WHF) Through Day 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Sorafenib-related Hand Foot Syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Sleep Condition Indicator score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Scar vascularity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Scar length
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Scar surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Readmission to any hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Day to day variability of sleep timing
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Thyroid hormone concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in plasma concentration of CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in plasma concentration of TNF-alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in plasma concentration of adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of BCR-ABL mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Inspiratory Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cross-sectional area of the C5 cervical root
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cross-sectional area of the C6 cervical root
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cross-sectional area of the C7 cervical root
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cross-sectional area of the radial nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cross-sectional area of the superficial radial nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cross-sectional area of the peroneal nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Malaria Incidence
Endpoint domain: Mortality/survival
Primary endpoint: VAS control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glycosylated Hemoglobin (HbA1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success rate of the therapeutic education program
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hematological relapse free survival
Endpoint domain: Mortality/survival
Primary endpoint: Correlation between CsA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Cervical Flexion Rotation Test (CFRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DWI parameters in thymic epithelial tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of corn beta-carotene
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Equivalency to provide vitamin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fresh frozen plasma transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Intestinal permeability changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Insomnia Severity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Actigraphy determined wake time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to estrogen therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of postpartum hemorrhage more than 1000 ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Degree of vaginal bacterial alpha diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean wheal diameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: NK cell response to the first peginterferon injection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of HBsAg-specific T cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gastric tube position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sensitivity, specificity, positive predictive value of endoscopic findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Vasogenic edema volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central arterial compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Isotonic Leg Press 1RM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety measured by blood chemistry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Tolerability measured by blood chemistry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Controlled hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time Weighted Sum of Pain Intensity Difference Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caesarean rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in foot pressure at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in quadriceps thickness at week 4, week 8 and week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nerve fiber layer/ganglion cell layer (NFL/GCL) abnormality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Resolution of Anterior Chamber Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 0 Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Reduction in Apical Radio-lucency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Absence of Apical Periodontitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase II dose (RP2D) of M7824
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in drug abuse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fear potentiation of acoustic startle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 28 Day All Cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Intra-fraction prostate motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome of death, myocardial infarction, stroke, valve thrombosis and hemorrhage
Endpoint domain: Mortality/survival
Primary endpoint: Healing rate by endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumorigenesis in seminomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pharmacokinetic of CS1 in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in respiratory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Composite of anthropometric measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short-term parental change in lethal means storage practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of opioid pills
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent of patients with moderate to severe pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of targeted saturation of 85% at 15 min of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With At Least One Treatment Emergent Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Schirmer Test Score, CFB at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to dissect fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC 0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Placebo-corrected change-from-baseline QTcF interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Early bactericidal activity (EBA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in The Anxiety Disorder Interview Schedule for DSM-IV
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Spence Child Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in asthma symptom frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in urgent, unscheduled, and emergency visits for asthma
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mycological culture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Subjects With Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with hip and knee prosthetic joint reinfection
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of IU of recFSH needed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in length-for-age Z-score (LAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Dose-limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Objective Response (OR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change of Toronto Rehabilitation Institute Hand Function Test (TRI-HFT) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual work participation score
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Annual health care utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Palatability Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Eye gaze patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circadian variation pattern of heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time-Weighted Average Change in RSV Load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Lesions With Gleason Score ≥ 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes from baseline in global cognitive composite score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes from baseline in macular degeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: RP score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: spontaneous AVF maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Pain interference with daily activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of MRD-negativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of metagenomic characteristics of the intestinal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in bacterial content of chronic leg ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Management of SVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HBV DNA non-detectability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver function normal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants tested at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants tested at 6-weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amplitude-integrated electroencephalography tracings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of patients with seroma formation
Endpoint domain: Adverse events/effects
Primary endpoint: number of patients with hernia recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Symptomatic, Culture Proven Urinary Tract Infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of patients without residual tumour on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plasma levels of rifampin and lopinavir-ritonavir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Derived Parasite Reduction Rate at 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum tolerated dose of APN401
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of adverse events of APN401
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage Changed in Adherence Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Symptom-free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug compliance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percent Change From Baseline in Calculated LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inter-compartmental Difference in Infliximab Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Post-operative Bleeding Events Specifically Related to the Target Bleeding Site (TBS)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Increase Blood Fibrinogen Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Positive bacterial culture yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in photoaged thinning of the treatment area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean/Median Numeric Rating Scale Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean/Median Opioid Consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline in Critical Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Focal Seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Alive at 3 Months
Endpoint domain: Mortality/survival
Primary endpoint: Decline in Neuropsychological Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Structural preservation of brain white matter and gray matter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluorescent intensity of ureter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent Sense of Competence Change Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mullen Scales of Early Learning Change Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vineland Adaptive Behavior Scales Change Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of patients with at least one adverse event (AE) or serious adverse event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with neurological changes during the follow-up period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of the intervertebral height in millimetres of the injected disc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maxillary Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excessive Fetal Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Fertility Problem Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence and severity of biopsy-proven acute rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: caesarean section rate
Endpoint domain: Mortality/survival
Primary endpoint: Rate of closure in venous ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Onset and progression of Alzheimer's Disease (AD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial high rate new episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax: Maximum Observed Plasma Concentration of E7090
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-t): Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration of E7090
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf): Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time of E7090
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in Range (70-140 mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ocular Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability Days
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in pain immediately after urethral pressure profilometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes